BETABiohacksAI is a research tool for informational purposes only. All outputs are computational hypothesis candidates — not confirmed mechanisms, not medical advice, and not a substitute for professional medical judgment. Independent experimental validation is always required.

FLT3 Modulators

COMPOUND CLUSTER

342 compoundscohesion 0.085cluster #4

The FLT3 Modulators cluster contains 342 compounds grouped by shared molecular target interactions, computed via Louvain community detection on the BiohacksAI target interaction graph.

Compounds in this Cluster

Afatinib297 studies Crizotinib298 studies Sorafenib300 studies Avapritinib246 studies trametinib296 studies pictilisib25 studies Sphingosine300 studies Acetic Acid Product of300 studies sp600125117 studies Swainsonine300 studies 1-(5,8-dihydro-1,4-dihydroxy-5,8-dioxo-2-naphthyl)-4-methylpent-3-en-1-yl cinnamate [Supplementary Concept]54 studies alsterpaullone12 studies hydroxyfasudil [Supplementary Concept]11 studies glaucarubinone10 studies ha10044 studies bdb chembl45746202 studies bdb syyqnyibifocps2 studies bdb chembl34019872 studies bdb chembl34019842 studies bdb pfhkagazrdertk2 studies bdb 3 adamantan 1 yl 1 6 2 6 dichlorophenyl 2 3 4 methylpiperazin 1 yl propyl amino 2 studies bdb chembl20180222 studies tyrphostin ag 12951 studies cediranib0 studies foretinib0 studies nintedanib0 studies tae 6840 studies r 4060 studies vandetanib0 studies kw 24490 studies rebastinib0 studies fedratinib0 studies tozasertib0 studies su 0148130 studies ast 4870 studies pazopanib0 studies midostaurin0 studies dovitinib0 studies pha 6657520 studies lestaurtinib0 studies bosutinib0 studies canertinib0 studies ponatinib0 studies raf 2650 studies danusertib0 studies doramapimod0 studies at 92830 studies erlotinib0 studies cyc 1160 studies milciclib0 studies defosbarasertib0 studies saracatinib0 studies azd 77620 studies cabozantinib0 studies tivozanib0 studies motesanib0 studies cep 324960 studies linifanib0 studies brigatinib0 studies k 252a0 studies pelitinib0 studies osi 6320 studies jnj 77066210 studies plx 47200 studies tandutinib0 studies quizartinib0 studies neratinib0 studies brivanib0 studies pf 038147350 studies ceritinib0 studies mln 80540 studies gefitinib0 studies alvocidib0 studies nilotinib0 studies enmd 20760 studies maleimide0 studies infigratinib0 studies ruboxistaurin0 studies pf 037583090 studies golvatinib0 studies lenvatinib0 studies defactinib0 studies ilorasertib0 studies regorafenib0 studies bms 7548070 studies pacritinib0 studies gilteritinib0 studies zotiraciclib0 studies bms 7776070 studies asp 30260 studies ucn 010 studies ibrutinib0 studies mk 24610 studies glesatinib0 studies semaxanib0 studies ruxolitinib0 studies imatinib0 studies aee 7880 studies abemaciclib0 studies dasatinib anhydrous0 studies bemcentinib0 studies masitinib0 studies gsk 10709160 studies enzastaurin0 studies orantinib0 studies crenolanib0 studies dabrafenib0 studies bafetinib0 studies bi 25360 studies sb 2035800 studies pf 005622710 studies lucitanib0 studies barasertib0 studies mk 51080 studies bms 3870320 studies bastadin 70 studies vatalanib0 studies silmitasertib0 studies upadacitinib0 studies tg100 1150 studies decernotinib0 studies tofacitinib0 studies pexidartinib0 studies rg 5470 studies azd 14800 studies whi p1310 studies amg 9000 studies momelotinib0 studies neflamapimod0 studies cudc 1010 studies filgotinib0 studies entrectinib0 studies gsk 6906930 studies baricitinib0 studies hematoxylin0 studies sb 2021900 studies gsk 4613640 studies sp 6001250 studies y 399830 studies sotrastaurin0 studies sgi 17760 studies at 75190 studies cerdulatinib0 studies fostamatinib0 studies lapatinib0 studies zanubrutinib0 studies palbociclib0 studies linsitinib0 studies capivasertib0 studies poziotinib0 studies merestinib0 studies sapitinib0 studies fgfr inhibitor debio 13470 studies dacomitinib anhydrous0 studies su 95160 studies fexagratinib0 studies gsk 10596150 studies seliciclib0 studies t3 clk0 studies ly 30091200 studies su 116520 studies tak 2850 studies 6bio0 studies pd 1730740 studies azd 54380 studies erdafitinib0 studies ly 28744550 studies tyrphostin 510 studies lorlatinib0 studies apitolisib0 studies go 69760 studies pi 1030 studies berzosertib0 studies sotuletinib0 studies uprosertib0 studies fasudil0 studies futibatinib0 studies sns 314 mesylate0 studies osi 9300 studies gw843682x0 studies dinaciclib0 studies ripasudil0 studies alectinib0 studies encorafenib0 studies acalabrutinib0 studies galunisertib0 studies atuveciclib0 studies dorsomorphin0 studies sra 7370 studies alisertib0 studies sulfuretin0 studies rociletinib0 studies indirubin 3 monoxime0 studies h3b 65270 studies pemigatinib0 studies fisogatinib0 studies spebrutinib0 studies hymenialdisine0 studies adavosertib0 studies ag12950 studies gw770249x0 studies verubulin0 studies osi 0270 studies tirabrutinib0 studies repotrectinib0 studies ravoxertinib0 studies iodoquinol0 studies gw559768x0 studies osimertinib0 studies tanzisertib0 studies varlitinib0 studies pha 6806320 studies zemirciclib0 studies canertinib dihydrochloride0 studies lorecivivint0 studies bms 3455410 studies hesperadin0 studies icotinib0 studies ritlecitinib0 studies norlichexanthone0 studies sar 407899 free base0 studies sunitinib malate0 studies sel 120 free base0 studies afuresertib0 studies sgx 5230 studies avutometinib0 studies pd 01662850 studies ribociclib0 studies entospletinib0 studies naporafenib0 studies aigialomycin d0 studies hydroxyfasudil0 studies demethylbellidifolin0 studies gf 1092030 studies leucettamine b0 studies mirdametinib0 studies selitrectinib0 studies gsk 269962a0 studies gw305074x0 studies selumetinib0 studies edicotinib0 studies cep 13470 studies epigalocatechin gallate0 studies vactosertib0 studies fruquintinib0 studies pralsetinib0 studies gw632580x0 studies lx 71010 studies olomoucine0 studies ci 10400 studies bisindolylmaleimide ix0 studies purvalanol b0 studies tak 7330 studies evobrutinib0 studies larotrectinib0 studies tolebrutinib0 studies netarsudil0 studies belumosudil0 studies y 276320 studies selpercatinib0 studies balanol0 studies gw779439x0 studies prexasertib0 studies cobimetinib0 studies sb 4315420 studies binimetinib0 studies pectolinarigenin0 studies delphinidin chloride0 studies tak 7150 studies naphthazalin0 studies elliptinium0 studies lavendustin c0 studies anilinopyrimidine10 studies hispidulin0 studies ro 3162330 studies isogranulatimide0 studies tyrphostin 250 studies lgh 4470 studies sb 2200250 studies talmapimod0 studies mebendazole0 studies bms 5829490 studies rivoceranib0 studies exelixis0 studies jnj 388776050 studies losmapimod0 studies olmutinib0 studies tomivosertib0 studies pd 1693160 studies tryptanthrin0 studies ph 7978040 studies rigosertib0 studies debromohymenialdisine0 studies meridianin c0 studies ulixertinib0 studies sorafenib tosylate0 studies tinodasertib0 studies sb5908850 studies rs roscovitine0 studies damnacanthal0 studies sb 2422350 studies volasertib0 studies tirbanibulin0 studies paullone 20 studies tepotinib0 studies meridianin d0 studies staurosporinone0 studies genkwanin0 studies curcumin pyrazole0 studies indigo0 studies as 6028680 studies gsk 180736a0 studies bx 7950 studies isoxanthohumol0 studies iodotubercidin0 studies imd 03540 studies zimlovisertib0 studies gsk 625137a0 studies granulatimide0 studies ic2610 studies 6 benzylaminopurine0 studies rabusertib0 studies bdb chembl20123972 studies cyanidin chloride0 studies tyrphostin 230 studies gsk 6503940 studies inamrinone0 studies asciminib0 studies acetoside0 studies indirubin 20 studies sangivamycin0 studies thymoquinone0 studies hypothemycin0 studies bergapten0 studies quinoxaline10 studies mubritinib0 studies azd 13900 studies 78 dihydroxyflavone0 studies rottlerin0 studies capmatinib0 studies selonsertib0 studies acridine orange0 studies